Todd Davis Biography and Net Worth

Todd C. Davis is Ligand’s Chief Executive Officer, a position he has held since December 2022, and has served as a member of the Board since March 2007. From 2006 until 2018, Mr. Davis was a Founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm which grew from zero to approximately $4 billion in capital commitments during his tenure. Previously, Mr. Davis served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories where he held several sales and marketing positions of increasing responsibility. Subsequently he led corporate development and held strategic planning and general management responsibilities at Elan Pharmaceuticals. Cumulatively he has almost thirty years of experience in both operations and investing in the biopharmaceutical and life sciences industries. Mr. Davis has been involved in over $3 billion of healthcare financings including growth equity, public equity turnarounds, structured debt and royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt transactions. Mr. Davis is a navy combat veteran and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently also serves on the boards of Palvella Therapeutics Inc. and ViroCell Biologics – both privately held companies. He is a former board member of the Harvard Business School Healthcare Alumni Association.

What is Todd C. Davis' net worth?: The estimated net worth of Todd C. Davis is at least $12.23 million as of August 8th, 2024. Mr. Davis owns 123,010 shares of Ligand Pharmaceuticals stock worth more than $12,225,226 as of April 8th. This net worth estimate does not reflect any other assets that Mr. Davis may own. Learn More about Todd C. Davis' net worth.
How do I contact Todd C. Davis?: The corporate mailing address for Mr. Davis and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at investors@ligand.com. Learn More on Todd C. Davis' contact information.
Has Todd C. Davis been buying or selling shares of Ligand Pharmaceuticals?: Todd C. Davis has not been actively trading shares of Ligand Pharmaceuticals during the last quarter. Most recently, on Thursday, August 8th, Todd C. Davis bought 2,500 shares of Ligand Pharmaceuticals stock. The stock was acquired at an average cost of $97.39 per share, with a total value of $243,475.00. Following the completion of the transaction, the chief executive officer now directly owns 123,010 shares of the company's stock, valued at $11,979,943.90. Learn More on Todd C. Davis' trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $243,475.00. During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 86,526 shares worth more than $8,524,068.88. The most recent insider tranaction occured on March, 4th when CFO Octavio Espinoza sold 5,000 shares worth more than $575,150.00. Insiders at Ligand Pharmaceuticals own 5.9% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 3/4/2025.

Todd C. Davis Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/8/2024	Buy	2,500	$97.39	$243,475.00	123,010
9/22/2023	Buy	4,000	$59.38	$237,520.00	73,090
2/10/2021	Sell	5,083	$213.14	$1,083,390.62	47,678
10/8/2018	Sell	2,500	$253.99	$634,975.00	42,556
8/17/2018	Sell	9,000	$239.78	$2,158,020.00	44,806
2/27/2018	Sell	17,170	$152.37	$2,616,192.90	65,898

Todd C. Davis Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $99.38

$99.93

$102.70

50 Day Range

MA: $112.76

$99.41

$122.23

2 Week Range

Now: $99.38

$67.72

$129.90

Volume

41,024 shs

Average Volume

122,706 shs

Market Capitalization

$1.91 billion

P/E Ratio

39.39

Dividend Yield

N/A

Beta

1.07